Visão geral da empresa
A clinical-stage biopharmaceutical entity, Can-Fite BioPharma Ltd. focuses on developing orally bioavailable small molecule therapeutic products designed for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction within the Israeli market. The company operates within the healthcare sector, specifically in the biotechnology industry, which implies a focus on research and development phases rather than established commercial sales volumes. Its current market capitalization stands at $6.88M, while reported annual revenue for the trailing twelve months is $405,000, supported by a workforce of 5 employees. These valuation and revenue figures indicate that the company remains in an early-stage development position with a minimal operational footprint, reflecting a business model where current income is insufficient to cover the substantial costs associated with bringing new drug candidates to market.
Saúde financeira
For the trailing twelve months, the company recorded revenue of $405,000 against a net income loss of $-9,828,000 and an EBITDA of $-9,926,000. The significant disparity between the nominal revenue and the substantial net income loss reveals a cost structure heavily weighted toward research and development expenses and operating overheads that far exceed current sales generation. Free cash flow for the period was $-4,985,750, indicating that the company is burning through cash reserves to fund its development pipeline without generating sufficient operational cash inflows to sustain operations independently. The gross margin stands at 100.0%, suggesting that the cost of goods sold is negligible relative to revenue, while the operating margin is -2488.7% and profit margin is 0.0%, highlighting the extreme inefficiency of current operations before accounting for R&D spend and the complete absence of bottom-line profitability. In terms of balance sheet strength, the company holds $8.54M in cash against $71,000 in debt, resulting in a debt-to-equity ratio of 1.27, which suggests a leveraged position relative to equity but one that is currently underpinned by significant liquidity. The current ratio is 3.46, indicating that the company possesses ample short-term assets to cover its short-term liabilities, providing a buffer despite the negative earnings. Return on Equity is -178.2% and Return on Assets is -66.7%, metrics that reveal management is currently generating negative returns on the capital invested in the firm due to the heavy financial drag of ongoing development costs.
Avaliação de valorização
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is -4.01, implying that the market is pricing in future earnings expectations that have not yet materialized in historical performance. The price-to-book ratio is 0.69, indicating that the market values the company at less than its book value, suggesting a discount relative to the net asset position often seen in pre-revenue biotech firms. Alternative valuation metrics show a price-to-sales ratio of 16.98 and an EV/EBITDA of -0.41, which suggests the market is valuing the company primarily on its potential pipeline rather than current earnings power or asset liquidity. Over the past year, the stock price ranged between a 52-week high of $36.40 and a 52-week low of $2.93, meaning the current trading price sits significantly below the yearly peak. The beta value is -0.10, a negative figure that indicates the stock's price volatility moves inversely to the broader market or behaves in a non-correlated manner, deviating from standard equity risk profiles.
Growth & Income
Revenue growth year-over-year is -43.3%, while earnings growth is N/A because the company reports losses in the current period and prior periods. Since the company is unprofitable, earnings cannot grow faster than revenue in a traditional sense, and the negative revenue growth indicates a contraction in sales volume or a cessation of commercial activity. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings are technically reinvested or retained, though in this case, the company is consuming cash reserves to fund operations. Consequently, the overall growth and income profile is characterized by a lack of current income generation and a contraction in top-line revenue, relying entirely on cash reserves to support the clinical-stage development pipeline.